A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women

    loading  Checking for direct PDF access through Ovid

Abstract

OBJECTIVE:

To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ≥ 35 (kg m-2) postcesarean delivery.

STUDY DESIGN:

Women with BMI ≥ 35 were randomized to receive prophylactic enoxaparin at a fixed dose of 40 mg daily or weight-based dosing of 0.5 mg kg-1 twice daily. The primary outcome was the proportion of subjects with peak anti-Xa levels in the prophylactic range of 0.2 to 0.6 IU ml-1.

RESULT:

From August 2013 through February 2014, 84 demographically similar women completed the protocol. In the weightbased group, 88% (37/42) of the women reached prophylactic anti-Xa levels versus 14% (6/42) in the fixed dose group (odds ratio 44.4, 95% confidence interval 12.44, 158.48, P < 0.001). No anti-Xa level exceeded 0.48 IU ml-1. There were no venous thromboembolic or bleeding events requiring reoperation or transfusion in either group.

CONCLUSION:

Compared with fixed dosing daily, weight-based dosing twice daily more effectively achieved prophylactic anti-Xa levels without reaching the therapeutic range.

Related Topics

    loading  Loading Related Articles